Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development

Julia A. Beaver; Laleh Amiri-Kordestani; Reena Philip; Patricia Cortazar

doi:10.1007/s12609-015-0183-2

Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development

Julia A. Beaver, Laleh Amiri-Kordestani, Reena Philip, Patricia Cortazar

Research output: Contribution to journal › Review article › peer-review

Abstract

In addition to reducing the size and extent of locally advanced breast cancer tumors, neoadjuvant trials allow for rapid assessment of drug efficacy and could expedite development and approval of treatments for early breast cancer. For these reasons, clinical trials in the neoadjuvant setting are prime opportunities to study translational science, pathologic response, genetic biomarkers, and imaging biomarkers. In this review, we provide a summary of the efforts to identify biomarkers aimed to understand tumor biology and to prognosticate and predict response to neoadjuvant therapy for early breast cancer. We also provide a perspective on how neoadjuvant trials can be used to pursue translational research and drug development.

Original language	English (US)
Pages (from-to)	151-160
Number of pages	10
Journal	Current Breast Cancer Reports
Volume	7
Issue number	3
DOIs	https://doi.org/10.1007/s12609-015-0183-2
State	Published - Sep 24 2015
Externally published	Yes

Keywords

Assessment
Biomarkers
Clinical trials
Drug development
Drug efficacy
Neoadjuvant trials

ASJC Scopus subject areas

Oncology

Access to Document

10.1007/s12609-015-0183-2

Fingerprint Dive into the research topics of 'Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development'. Together they form a unique fingerprint.

Cite this

@article{e5b208d568464a24b095065d82a9ada9,

title = "Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development",

abstract = "In addition to reducing the size and extent of locally advanced breast cancer tumors, neoadjuvant trials allow for rapid assessment of drug efficacy and could expedite development and approval of treatments for early breast cancer. For these reasons, clinical trials in the neoadjuvant setting are prime opportunities to study translational science, pathologic response, genetic biomarkers, and imaging biomarkers. In this review, we provide a summary of the efforts to identify biomarkers aimed to understand tumor biology and to prognosticate and predict response to neoadjuvant therapy for early breast cancer. We also provide a perspective on how neoadjuvant trials can be used to pursue translational research and drug development.",

keywords = "Assessment, Biomarkers, Clinical trials, Drug development, Drug efficacy, Neoadjuvant trials",

author = "Beaver, {Julia A.} and Laleh Amiri-Kordestani and Reena Philip and Patricia Cortazar",

year = "2015",

month = sep,

day = "24",

doi = "10.1007/s12609-015-0183-2",

language = "English (US)",

volume = "7",

pages = "151--160",

journal = "Current Breast Cancer Reports",

issn = "1943-4588",

publisher = "Current Science, Inc.",

number = "3",

}

TY - JOUR

T1 - Neoadjuvant Breast Cancer Trials

T2 - Translational Research in Drug Development

AU - Beaver, Julia A.

AU - Amiri-Kordestani, Laleh

AU - Philip, Reena

AU - Cortazar, Patricia

PY - 2015/9/24

Y1 - 2015/9/24

N2 - In addition to reducing the size and extent of locally advanced breast cancer tumors, neoadjuvant trials allow for rapid assessment of drug efficacy and could expedite development and approval of treatments for early breast cancer. For these reasons, clinical trials in the neoadjuvant setting are prime opportunities to study translational science, pathologic response, genetic biomarkers, and imaging biomarkers. In this review, we provide a summary of the efforts to identify biomarkers aimed to understand tumor biology and to prognosticate and predict response to neoadjuvant therapy for early breast cancer. We also provide a perspective on how neoadjuvant trials can be used to pursue translational research and drug development.

AB - In addition to reducing the size and extent of locally advanced breast cancer tumors, neoadjuvant trials allow for rapid assessment of drug efficacy and could expedite development and approval of treatments for early breast cancer. For these reasons, clinical trials in the neoadjuvant setting are prime opportunities to study translational science, pathologic response, genetic biomarkers, and imaging biomarkers. In this review, we provide a summary of the efforts to identify biomarkers aimed to understand tumor biology and to prognosticate and predict response to neoadjuvant therapy for early breast cancer. We also provide a perspective on how neoadjuvant trials can be used to pursue translational research and drug development.

KW - Assessment

KW - Biomarkers

KW - Clinical trials

KW - Drug development

KW - Drug efficacy

KW - Neoadjuvant trials

UR - http://www.scopus.com/inward/record.url?scp=84940440696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940440696&partnerID=8YFLogxK

U2 - 10.1007/s12609-015-0183-2

DO - 10.1007/s12609-015-0183-2

M3 - Review article

AN - SCOPUS:84940440696

VL - 7

SP - 151

EP - 160

JO - Current Breast Cancer Reports

JF - Current Breast Cancer Reports

SN - 1943-4588

IS - 3

ER -